<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809481</url>
  </required_header>
  <id_info>
    <org_study_id>ERGCR-18-ORGHIT-001</org_study_id>
    <nct_id>NCT03809481</nct_id>
  </id_info>
  <brief_title>An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban</brief_title>
  <acronym>HITSOVA</acronym>
  <official_title>An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects With Acute HIT (HITSOVA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aspen Global Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aspen Global Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the
      Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT
      (HITSOVA study)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      Primary:

      To show that for the treatment of subjects with acute heparin-induced thrombocytopenia (HIT)
      danaparoid use is not inferior to argatroban in terms of efficacy. The primary efficacy
      endpoint (composite endpoint) is defined as treatment response at Day 44.

      A subject will be considered a treatment responder, if none of the following events occur by
      Day 44:

        -  New or extended venous and/or arterial thrombosis, including gangrene/skin necrosis
           Note: 'thrombosis' denotes venous and/or arterial here and throughout the protocol

        -  All-cause mortality

        -  Unplanned amputation, including ischemic gut resection

      Secondary/Exploratory:

      To collect additional efficacy data

        -  Percentage of subjects with consistent increases in platelets at days 3, 5, and 7
           (evidence of early response), defined as monotonically increasing platelet counts,
           measured 2 days apart on days 3 (±1 day), 5 (±1 day) and 7 (±1 day).

        -  Deaths due to TE or bleeding up until Day 44

        -  Incidence of fatal or non-fatal major bleeding up until Day 44

      Note: As outlined by the Control of Anticoagulation Subcommittee major bleeding in
      non-surgical subjects is defined as:

        1. Fatal bleeding, and/or

        2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal,
           intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with
           compartment syndrome, and/or

        3. Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/ L) or more, or leading
           to transfusion of two or more units of whole blood or red cells

             -  New or extended thrombosis, including gangrene/skin necrosis

             -  Unplanned amputation, including ischemic gut resection

             -  All-cause mortality

      Exploratory

        -  Time to first event (new/extended thrombosis, all cause mortality, unplanned amputation)

        -  Time to reach consistent increase in 3 consecutive alternate day platelet count
           measurements during acute treatment

        -  Incidence of new or extended TE events, including gangrene/skin necrosis up until Day 14

        -  Incidence of all-cause mortality up until Day 14

        -  Incidence of unplanned amputation up until Day 14

        -  Incidence of fatal or non-fatal major bleeding up until Day 14

      To describe the safety of danaparoid in comparison to argatroban

        -  All-cause mortality

        -  Incidence of fatal and non-fatal major bleeding events (as defined above) during the
           acute treatment and then the entire follow-up period (until Day 44)

        -  Incidence of serious adverse events (SAEs)

        -  Incidence of adverse events (AEs)

        -  Changes in vital parameters (heart rate, blood pressure, and respiratory rate) and
           12-lead electrocardiogram (ECG)

        -  Incidence of positive pre-danaparoid cross reactivity in the Heparin-induced Platelet
           Activation (HIPA) assay (Greinacher. 1991)

        -  Safety laboratory parameters

      Design: This is a Phase 3, open-label, randomized, active-controlled, multi-center study to
      evaluate the safety and efficacy of danaparoid versus argatroban in treatment of subjects
      with acute HIT. If available, a screening HIT test will be performed for subjects who may be
      eligible to participate in the study. Subjects who test negative using the in-house screening
      test will not be considered for study enrollment.

      If the test is not available and for those that tested positive using the test, subjects who
      develop a reduction in platelet count (PC) greater than or equal to 30% compared with the
      higher of their pre-heparin treatment count or their highest platelet count after the start
      of heparin either

        1. Between Days 4 and 14 of the start of heparin treatment with or without thrombosis OR

        2. At Day 1 of heparin treatment and recent heparin exposure (within the last 30 days with
           or without thrombosis) and who have a score on the 4Ts test of &gt;3 will be considered for
           study enrollment as a Suspected HIT.

             -  The following will occur for all subjects (regardless of whether they had a
                screening HIT test performed in the enrolling hospital or not): All heparin
                administration must immediately cease including the use of heparin-bonded vascular
                access catheters and circuits as well as heparin flushes.

             -  The subject will be randomized to receive 1 of the 2 study drugs after written
                informed consent has been obtained

             -  The subject will initiate the treatment based on clinical evaluation of the
                Investigator, at the same time a blood sample for HIT anti- antibodies and cross
                reactivity will be obtained

      HIT diagnosis will be determined by clinical signs suggestive of HIT and confirmed
      serologically by the HIPA assay and a specific ELISA test for the HIT IgG.

      Subjects with a positive HIPA assay and IgG antigen test with optical density (OD) &gt; 0.5will
      be classified as Confirmed HIT and treatment with randomized study drug will continue.

      Subjects with negative HIPA assay and a strongly positive HIT IgG antigen test with an
      optical density (OD) &gt;1.5 and a 4Ts score &gt;3 will be classified as suspected HIT and
      treatment with randomized study drug will continue. These subjects will be adjudicated
      retrospectively by the Adjudication Committee (AdjC) and then grouped into highly likely HIT
      or non-HIT.

      All other subjects will be considered as non-HIT and the subjects will be removed from the
      protocol, study drug will be discontinued, and further procedures and treatment will be given
      at the discretion of the Investigator according to local standard practice. These subjects
      will be followed to Day 44 after their first dose of study drug for assessment of safety If
      it becomes necessary during the treatment period for an operation, invasive vascular
      procedure or acute kidney injury requiring the use of an extracorporeal circulation machine
      develops, then specific dosing instructions are available.

      If the acute kidney injury does not recover during the treatment period and the use of an
      extracorporeal circulation machine is required longer, then the subject will not be eligible
      to be included in the per protocol set (PPS), but will still be eligible to be included in
      the full analysis set (FAS).

      Study Population: All subjects who develop a reduction in platelet count (PC) ≥ 30% compared
      to the higher of their pre-heparin treatment count or their highest platelet count after the
      start of heparin at either a) between Days 4 and 14 of the start of heparin treatment with or
      without thrombosis or b) at Day 1 of heparin treatment (and recent heparin exposure within
      the last 30 days) with or without thrombosis and who have a score on the 4Ts test of &gt;3 and
      who are later confirmed to have HIT or highly likely HIT by the HIPA assay or HIT IgG or by
      the AdjC If available, a screening HIT test will be performed on subjects by the laboratory
      of the enrolling hospital and subjects testing negative will not be enrolled . Clinical signs
      of HIT are:

        -  New thrombosis, especially on both sides of the circulation

        -  Acute systemic reaction when heparin bolus was given

        -  Transient global amnesia

        -  White clot syndrome

        -  Skin necrosis

        -  Occlusion of an extracorporeal circuit
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, randomized, active-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Efficacy Response</measure>
    <time_frame>Day 44</time_frame>
    <description>A subject will be considered a treatment responder if none of the following occur: New or extended thrombosis, all-cause mortality, unplanned amputation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consistent increases in platelet count</measure>
    <time_frame>Days 3, 5, and 7</time_frame>
    <description>Consistent increases in platelets at days 3, 5, and 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to TE or bleeding</measure>
    <time_frame>Day 44</time_frame>
    <description>Death due to TE or bleedin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>Day 44</time_frame>
    <description>Fatal or non-fatal bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New or extended thrombosis</measure>
    <time_frame>Day 44</time_frame>
    <description>New of extended thrombosis, including gangrene/skin necrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned amputation</measure>
    <time_frame>Day 44</time_frame>
    <description>Unplanned amputation, including ischemic gut resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 44</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">508</enrollment>
  <condition>Heparin-induced Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Danaparoid Sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive danaparoid via IV infusion for at least 7 days then transition to a VKA. IV loading bolus injection of 2250 U, followed by 400 U/h for 4 hours, then 300 U/h for 4 hours, then a maintenance infusion of 150-200 U/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Argatroban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive argatroban 2 microgram/kg/min as a continuous infusion, titrated to an aPTT that is 1.5 to 3.0 x initial baseline value, but not exceeding 100 seconds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danaparoid Sodium</intervention_name>
    <description>inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation</description>
    <arm_group_label>Danaparoid Sodium</arm_group_label>
    <other_name>Orgaran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Argatroban</intervention_name>
    <description>Synthetic direct thrombin inhibitor</description>
    <arm_group_label>Argatroban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At the time of enrolment subjects are eligible to be included in the study only if all
             of the following criteria apply:

               1. Signed written informed consent by the subject, or if the subject is temporarily
                  unable to do so, then consent will be sought from a family member, or a legally
                  accepted representative as per local regulations

               2. Males or females aged ≥2 weeks

               3. Subjects with suspected HIT by 4Ts of &gt;3 and with reduction of platelet count of
                  ≥ 30% at either:

                    1. Between Day 4 and 14 of the start of heparin exposure or

                    2. At Day 1 of heparin exposure with pre-treatment with heparin within the last
                       30 days, with or without thrombosis.

               4. Have adequate renal function: Glomerular filtration rate ≥ 15 mL/min/1.73 m²

               5. Male participants:

                  A male participant must agree to use contraception during the treatment period
                  and for at least 5 days after the last dose of study intervention and refrain
                  from donating sperm during this period.

               6. Female participants:

                  A female participant is eligible to participate if 1 of the following conditions
                  applies:

                    1. Not a woman of childbearing potential OR

                    2. A woman of childbearing potential who agrees to follow the contraceptive
                       guidance during the treatment period and for at least 5 days corresponding
                       to time needed to eliminate study intervention. (Subjects taking oral
                       contraceptives or hormone replacement therapy must have a stable dose and
                       regimen for ≥ 3 months prior to entry into the study.)

               7. Understanding/willingness by the subject or his/her legally accepted
                  representative to participate in the clinical study and ability to comply with
                  study procedures and the study visit schedule

        Exclusion Criteria:

          -  At the time of enrolment subjects are excluded from the study if any of the following
             criteria apply:

               1. Premature infants (corrected age &lt;37 weeks gestational age)

               2. Expectation of cardiac surgery within the next 44 days

               3. Life expectancy clearly less than the 44 days

               4. Fibrinolytic therapy &lt;24 hours before enrolment

               5. Lumbar puncture or spinal/epidural catheter placement within the past 48 hours

               6. Severe hepatic impairment (Child-Pugh Class C)

               7. Active bleeding

               8. Subjects with the following conditions to be excluded if alternative
                  antithrombotic treatments are available:

                  (i) Severe hemorrhagic diathesis, (ii) Damage to the central nervous system (iii)
                  Brain, spinal or ophthalmologic surgery are to be excluded if alternative
                  antithrombotic treatments are available.

                  (iv) Active stomach/duodenal ulcers or active peptic ulcer unless this ulcer is
                  the cause of the surgical procedure

               9. An unexplained activated partial thromboplastin time (aPTT) &gt; 2 x the normal
                  range

              10. A hemorrhagic cerebrovascular accident within the previous 3 months

              11. Severe, uncontrolled hypertension defined as blood pressure &gt;180/110 mmHg

              12. Diabetic retinopathy

              13. Acute bacterial endocarditis

              14. Expectation of a long-term (&gt; 3 weeks) hemodialysis requirement before the end of
                  the acute treatment

              15. Hypersensitivity to the active substances or to any of the excipients

              16. Hypersensitivity to sulphite

              17. Any investigational drug(s) use within 4 weeks preceding Screening or anticipated
                  use during the course of the study

              18. Pregnant or breastfeeding woman

              19. Use of intra-aortic balloon pump, or ventricular assist device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shands University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center, 516 S=Delaware St SE</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of the Republic of Srpska, Medical Intesnive Care Unit</name>
      <address>
        <city>Banja Luka</city>
        <state>Republika Srpska</state>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre of the Republic of Srpska, Clinic for cardiology</name>
      <address>
        <city>Banja Luka</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre of the Republic of Srpska, Lung Clinic</name>
      <address>
        <city>Banja Luka</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center University of Sarajevo, Clinic for Heart, Blood Vessels and Rheumatic Diseases</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center University of Sarajevo, Clinic for Lung Diseases</name>
      <address>
        <city>Sarajevo</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital; 501 Smyth Road</name>
      <address>
        <city>Ottawa</city>
        <state>Ottowa</state>
        <zip>K1H 8l6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3755 Chemin de la Cote Sainte Catherine Room B 304-17</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Zagreb, Clinic for Internal Diseases, Department for Hematology</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno, Dept. of Clinical Hematology</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava, Dept. of Hematooncology</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIJON University Hospital</name>
      <address>
        <city>Dijon</city>
        <state>Burgundy</state>
        <zip>2100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne; Avenue Albert Raimond</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <state>Rhone- Alpes</state>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <state>Somme</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichhain Hämophiliezentrum, Gerinnungssprechstunde Landsberger Allee 49</name>
      <address>
        <city>Berlin</city>
        <state>Berlin-Brandenburg</state>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichhain Hämophiliezentrum</name>
      <address>
        <city>Berlin</city>
        <state>Brandenburg</state>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH, Klinik für Herz-, Kinderherz- und Gefäßchirurgie Standort Gießen</name>
      <address>
        <city>Gießen</city>
        <state>Hesse</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH, Klinik für Herz-, Kinderherz- und Gefäßchirurgie Standort Gießen</name>
      <address>
        <city>Giesen</city>
        <state>Lower Saxony</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatstklinikum Halle (Saale), Medizinische Klinik III</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Saxony-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinkum Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>1067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Greifswald Dpt. of Hematology</name>
      <address>
        <city>Greifswald</city>
        <zip>17489</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Klinische Transfusionsmedizin</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen György Országos Kardiológiai Intézet; Haller utca 29.</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Heart and Vascular Center, Varosmajor u. 68</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DE OEC Thrombosis és Haemostasis Központ</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria S.Orsola-Malpighi - UO Angiologia e Malattie della Coagulazione</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Careggi, SOD Malattie Aterotrombotiche</name>
      <address>
        <city>Firenze</city>
        <state>Florence</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XIII, Servizio di Immunoematologia e Medicina Trasfusionale</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardy</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ca'Grande Ospedale Maggiore Policlinico - UOC Medicina Generale - Emostasi e Trombosi</name>
      <address>
        <city>Milano</city>
        <state>Lombardy</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital- Thrombosis Center</name>
      <address>
        <city>Milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Scientifico San Raffaele- Servizio Coagulazione e Centro Trombosi</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne. ul. Dębinki 7; 80-952</name>
      <address>
        <city>Gdańsk</city>
        <state>Greater Poland Voivodeship</state>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne HCP Sp. z o.o. Szpital im. Św. Jana Pawła II</name>
      <address>
        <city>Poznań</city>
        <zip>61485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 2 Pomorskiej Akademii Medycznej Klinika Chirurgii Naczyniowej, Ogólnej i Angiologii</name>
      <address>
        <city>Szczecin</city>
        <zip>71-899</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Zespolony im. L. Rydygiera</name>
      <address>
        <city>Toruń</city>
        <zip>87100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Invasive Cardiology Department Chair and Department of Cardiology Medical University in Lodz, Bieganski Hospital</name>
      <address>
        <city>Łódź</city>
        <zip>91347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First City Hospital N.A. E.E. Volosevich</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Hospital 67</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Center</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital after N.N Burdenko</name>
      <address>
        <city>Penza</city>
        <zip>440026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital № 122 N. A. L.G. Sokolov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiovasklar Diseases of Vojvodina, Cardiac Surgery ICU</name>
      <address>
        <city>Sremska Kamenica</city>
        <state>Novi Sad</state>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiovaskular Diseases of Vojvodina, Cardiology ICU</name>
      <address>
        <city>Sremska Kamenica</city>
        <state>Novi Sad</state>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute for Pulmonary Disease of Vojvodina, Pulmonary thromboembolism department</name>
      <address>
        <city>Novi Sad</city>
        <state>Sremska Kamenica</state>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia, Clinic for Emergency Internal Medicine</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical centre of Serbia, Clinic for Pulmonology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instiute of Cardiovascular Diseases &quot;Dedinje&quot;</name>
      <address>
        <city>Belgrade</city>
        <zip>11040</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre &quot;Bezanijska kosa&quot;, Department of Cardiology</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 17, 2019</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Danaparoid</mesh_term>
    <mesh_term>Argatroban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

